Mehrnoosh Shanaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mehrnoosh Shanaki has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Ali Rahimipour
Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 shared publications - Solaleh Emamgholipour
Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications Abolfazl Omidifar
Department of Medical Laboratory Sciences School of Allied Medical Sciences Student Research Committee Shahid Beheshti University of Medical Sciences Tehran Iran
4 shared publications- Nariman Moradi
Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
4 shared publications - Behnam Alipoor
Department of Laboratory Sciences, Faculty of Paramedicine, Yasuj University of Medical Sciences, Yasuj, Iran
3 shared publications - Faranak Kazerouni
Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Development and validation of an in-house one-step RT-qPCR method for the quantification of the BCR::ABL1 p210 transcripts
Chronic myeloid leukemia (CML) is driven by the BCR::ABL1 fusion oncogene, with the p210 transcript accounting for over 98% of cases. RT-qPCR monitoring of the BCR::ABL1 fusion gene is the gold standard for detecting measurable residual disease (MRD) and guiding treatment-free remission (TFR) decisions. Most commercial assays are costly and limit accessibility in resource-constrained settings. We aimed to develop and validate an in-house one-step RT-qPCR assay for BCR::ABL1 p210 with high analytical sensitivity and precision. The assay was optimized and validated following CLSI guidelines. In-house plasmid standards were calibrated against internationally certified ERM-AD623 reference material. Analytical performance (specificity, sensitivity, precision, and linearity) and clinical validation were performed using 34 patient samples against the CE-IVD certified geneMAP BCR::ABL1 p210 IS-MMR kit. The assay demonstrated a low limit of detection (LoD) of 0.0030% BCR::ABL1/ABL1 ratio, corresponding approximately to an MR4.51-equivalent level, enabling reliable detection of low-level transcripts. No cross-reactivity with p190 variants was observed. Strong linearity was demonstrated across the MR1-equivalent to MR4.5-equivalent range. Precision met predefined acceptance criteria, with standard deviations below 0.28 MR units. Clinical validation demonstrated excellent correlation with the reference kit (Pearson's r = 0.979). This validated in-house assay demonstrates commercial-grade analytical performance, offering a cost-effective and accessible approach for reliable deep molecular response (DMR) assessment in local and research-oriented CML monitoring, particularly in resource-limited settings.
- 15 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessDevelopment and validation of an in-house one-step RT-qPCR method for the quantification of the BCR::ABL1 p210 transcripts
Chronic myeloid leukemia (CML) is driven by the BCR::ABL1 fusion oncogene, with the p210 transcript accounting for over 98% of cases. RT-qPCR monitoring of the BCR::ABL1 fusion gene is the gold standard for detecting measurable residual disease (MRD) and guiding treatment-free remission (TFR) decisions. Most commercial assays are costly and limit accessibility in resource-constrained settings. We aimed to develop and validate an in-house one-step RT-qPCR assay for BCR::ABL1 p210 with high analytical sensitivity and precision. The assay was optimized and validated following CLSI guidelines. In-house plasmid standards were calibrated against internationally certified ERM-AD623 reference material. Analytical performance (specificity, sensitivity, precision, and linearity) and clinical validation were performed using 34 patient samples against the CE-IVD certified geneMAP BCR::ABL1 p210 IS-MMR kit. The assay demonstrated a low limit of detection (LoD) of 0.0030% BCR::ABL1/ABL1 ratio, corresponding approximately to an MR4.51-equivalent level, enabling reliable detection of low-level transcripts. No cross-reactivity with p190 variants was observed. Strong linearity was demonstrated across the MR1-equivalent to MR4.5-equivalent range. Precision met predefined acceptance criteria, with standard deviations below 0.28 MR units. Clinical validation demonstrated excellent correlation with the reference kit (Pearson's r = 0.979). This validated in-house assay demonstrates commercial-grade analytical performance, offering a cost-effective and accessible approach for reliable deep molecular response (DMR) assessment in local and research-oriented CML monitoring, particularly in resource-limited settings.
- 11 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Curcumin and acute myeloid leukemia: a golden hope, updated insights
Acute myeloid leukemia (AML) is marked by uncontrolled growth of malignant cells in the bone marrow, presenting a major challenge in hematology despite treatment advances. Curcumin, a polyphenol from turmeric, shows promise as an anticancer agent with multiple mechanisms targeting pathways like NF-κB, STAT3, PI3K/AKT, and MAPK. This review highlights curcumin’s antileukemic effects, including apoptosis induction, cell proliferation inhibition, and angiogenesis modulation. Although low bioavailability limits its clinical use, nanoformulations such as liposomes and micelles have improved curcumin’s stability and uptake. Combining curcumin with standard chemotherapies has shown synergistic effects, enhancing anticancer efficacy. Preclinical studies consistently demonstrate curcumin’s antileukemic impact in AML cell lines and animal models, showing reduced tumor load and prolonged survival. Ongoing clinical trials are assessing curcumin’s safety and efficacy in AML patients, with early results indicating potential. However, larger randomized trials are needed for confirmation. In conclusion, curcumin’s anticancer properties and safety profile make it a valuable candidate for AML treatment. Further research is necessary to refine delivery methods, optimize combination therapies, and substantiate its role through clinical trials.
- 11 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Curcumin and acute myeloid leukemia: a golden hope, updated insights
Acute myeloid leukemia (AML) is marked by uncontrolled growth of malignant cells in the bone marrow, presenting a major challenge in hematology despite treatment advances. Curcumin, a polyphenol from turmeric, shows promise as an anticancer agent with multiple mechanisms targeting pathways like NF-κB, STAT3, PI3K/AKT, and MAPK. This review highlights curcumin’s antileukemic effects, including apoptosis induction, cell proliferation inhibition, and angiogenesis modulation. Although low bioavailability limits its clinical use, nanoformulations such as liposomes and micelles have improved curcumin’s stability and uptake. Combining curcumin with standard chemotherapies has shown synergistic effects, enhancing anticancer efficacy. Preclinical studies consistently demonstrate curcumin’s antileukemic impact in AML cell lines and animal models, showing reduced tumor load and prolonged survival. Ongoing clinical trials are assessing curcumin’s safety and efficacy in AML patients, with early results indicating potential. However, larger randomized trials are needed for confirmation. In conclusion, curcumin’s anticancer properties and safety profile make it a valuable candidate for AML treatment. Further research is necessary to refine delivery methods, optimize combination therapies, and substantiate its role through clinical trials.
- Open Access
- 25 February 2023
- Published by Springer Nature in BMC Research Notes
- Vol. 16 (1) , 1-10
The high-intensity interval training (HIIT) and curcumin supplementation can positively regulate the autophagy pathway in myocardial cells of STZ-induced diabetic rats
Objective: Targeting autophagy is a new therapeutic strategy for the complications of diabetes,such as diabetic cardiomyopathy (DCM). During diabetes, increased or insufficient autophagic activity causes aberrations in cellular homeostasis. Regarding the conflicting and unclear results regarding the effect of HIIT and curcumin supplementation on the expression of genes associated to autophagy, this study aimed to assess whether 4-week high-intensity interval training (HIIT) and curcumin supplementation are able to influence the expression of autophagy-related genes in myocardial cells of diabetic rats. Methods: In an experimental design, 24 male Wistar rats were randomly divided into 4 groups: non-diabetic control (NC), diabetic control (DC), diabetes + HIIT (D + HIIT), and diabetes + curcumin (D + CU). After HIIT program and curcumin treatment, the genes expression of autophagy pathway were assessed in the myocardium by real-time PCR Tanique. Results: The results indicated that the expression levels of ATG1, Beclin1, ATG5, and LAMP-2 genes were significantly reduced in the DC group compared to the NC group (p < 0.001). Following 4-week HIIT, the expression of Beclin1, ATG-5, and LAMP-2 improved considerably compared to the DC group (p < 0.001, p < 0.001, and p < 0.05, respectively). In addition, after 4 weeks of curcumin supplementation, the expression levels of ATG-5 and Beclin-1 were significantly improved compared to the DC group (p < 0.001, p < 0.05, respectively). It seems HIIT and curcumin supplementation can be an effective approach for inducing autophagy and improving cardiac function in DCM rats.However, HIIT seems more effective than curcumin in this regard.
- 25 February 2023
- Published by Springer Nature in BMC Research Notes
- Vol. 16 (1) , 1-10
Open AccessThe high-intensity interval training (HIIT) and curcumin supplementation can positively regulate the autophagy pathway in myocardial cells of STZ-induced diabetic rats
Objective: Targeting autophagy is a new therapeutic strategy for the complications of diabetes,such as diabetic cardiomyopathy (DCM). During diabetes, increased or insufficient autophagic activity causes aberrations in cellular homeostasis. Regarding the conflicting and unclear results regarding the effect of HIIT and curcumin supplementation on the expression of genes associated to autophagy, this study aimed to assess whether 4-week high-intensity interval training (HIIT) and curcumin supplementation are able to influence the expression of autophagy-related genes in myocardial cells of diabetic rats. Methods: In an experimental design, 24 male Wistar rats were randomly divided into 4 groups: non-diabetic control (NC), diabetic control (DC), diabetes + HIIT (D + HIIT), and diabetes + curcumin (D + CU). After HIIT program and curcumin treatment, the genes expression of autophagy pathway were assessed in the myocardium by real-time PCR Tanique. Results: The results indicated that the expression levels of ATG1, Beclin1, ATG5, and LAMP-2 genes were significantly reduced in the DC group compared to the NC group (p < 0.001). Following 4-week HIIT, the expression of Beclin1, ATG-5, and LAMP-2 improved considerably compared to the DC group (p < 0.001, p < 0.001, and p < 0.05, respectively). In addition, after 4 weeks of curcumin supplementation, the expression levels of ATG-5 and Beclin-1 were significantly improved compared to the DC group (p < 0.001, p < 0.05, respectively). It seems HIIT and curcumin supplementation can be an effective approach for inducing autophagy and improving cardiac function in DCM rats.However, HIIT seems more effective than curcumin in this regard.
- Open Access
- 6 January 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-12
Alterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues in obese women
Animal model studies suggest that change in the members of the suppressor of the cytokine signaling (SOCS) family (mainly SOCS1 and SOCS3) is linked to the pathogenesis of obesity-related metabolic disorders. Moreover, epigenetic modification is involved in the transcriptional regulation of the SOCS gene family. Here, we aimed to evaluate the mRNA expression as well as gene promoter methylation of SOCS1 and SOCS3 in subcutaneous adipose tissue (SAT) from obese women compared to normal-weight subjects. We also intend to identify the possible association of SOCS1 and SOCS3 transcript levels with metabolic parameters in the context of obesity. This study was conducted on women with obesity (n = 24) [body mass index (BMI) ≥ 30 kg/m 2] and women with normal-weight (n = 22) (BMI < 25 kg/m 2). Transcript levels of SOCS1 and SOCS3 were evaluated by real-time PCR in SAT from all participants. After bisulfite treatment of DNA, methylation-specific PCR was used to assess the putative methylation of 10 CpG sites in the promoter of SOCS1 and 13 CpG sites in SOCS3 in SAT from women with obesity and normal weight. It was found that unlike SOCS3, which disclosed an elevating expression pattern, the expression level of SOCS1 was lower in the women with obesity as compared with their non‐obese counterparts (P-value = 0.03 for SOCS1 transcript level and P-value = 0.011 for SOCS3 transcript level). As for the analysis of promoter methylation, it was found that SOCS1 and SOCS3 methylation were not significantly different between the individuals with obesity and normal weight (P-value = 0.45 and P-value = 0.89). Correlation analysis indicated that the transcript level of SOCS1 mRNA expression had an inverse correlation with BMI, hs-CRP levels, HOMA-IR, and insulin levels. However, the SOCS3 transcript level showed a positive correlation with BMI, waist-to-height ratio, waist circumference, hip circumference, hs-CRP, HOMA-IR, insulin, fasting blood glucose, and total cholesterol. Interestingly, HOMA-IR is the predictor of the transcript level of SOCS1 (β = − 0.448, P-value = 0.003) and SOCS3 (β = 0.465, P-value = 0.002) in SAT of all participants. Our findings point to alterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues from women with obesity. Moreover, mRNA expression of SOCS1 and SOCS3 in SAT was associated with known obesity indices, insulin resistance, and hs-CRP, suggesting the contribution of SOCS1 and SOCS3 in the pathogenesis of obesity-related metabolic abnormalities. However, further studies are required to establish this concept.
- 6 January 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-12
Open AccessAlterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues in obese women
Animal model studies suggest that change in the members of the suppressor of the cytokine signaling (SOCS) family (mainly SOCS1 and SOCS3) is linked to the pathogenesis of obesity-related metabolic disorders. Moreover, epigenetic modification is involved in the transcriptional regulation of the SOCS gene family. Here, we aimed to evaluate the mRNA expression as well as gene promoter methylation of SOCS1 and SOCS3 in subcutaneous adipose tissue (SAT) from obese women compared to normal-weight subjects. We also intend to identify the possible association of SOCS1 and SOCS3 transcript levels with metabolic parameters in the context of obesity. This study was conducted on women with obesity (n = 24) [body mass index (BMI) ≥ 30 kg/m 2] and women with normal-weight (n = 22) (BMI < 25 kg/m 2). Transcript levels of SOCS1 and SOCS3 were evaluated by real-time PCR in SAT from all participants. After bisulfite treatment of DNA, methylation-specific PCR was used to assess the putative methylation of 10 CpG sites in the promoter of SOCS1 and 13 CpG sites in SOCS3 in SAT from women with obesity and normal weight. It was found that unlike SOCS3, which disclosed an elevating expression pattern, the expression level of SOCS1 was lower in the women with obesity as compared with their non‐obese counterparts (P-value = 0.03 for SOCS1 transcript level and P-value = 0.011 for SOCS3 transcript level). As for the analysis of promoter methylation, it was found that SOCS1 and SOCS3 methylation were not significantly different between the individuals with obesity and normal weight (P-value = 0.45 and P-value = 0.89). Correlation analysis indicated that the transcript level of SOCS1 mRNA expression had an inverse correlation with BMI, hs-CRP levels, HOMA-IR, and insulin levels. However, the SOCS3 transcript level showed a positive correlation with BMI, waist-to-height ratio, waist circumference, hip circumference, hs-CRP, HOMA-IR, insulin, fasting blood glucose, and total cholesterol. Interestingly, HOMA-IR is the predictor of the transcript level of SOCS1 (β = − 0.448, P-value = 0.003) and SOCS3 (β = 0.465, P-value = 0.002) in SAT of all participants. Our findings point to alterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues from women with obesity. Moreover, mRNA expression of SOCS1 and SOCS3 in SAT was associated with known obesity indices, insulin resistance, and hs-CRP, suggesting the contribution of SOCS1 and SOCS3 in the pathogenesis of obesity-related metabolic abnormalities. However, further studies are required to establish this concept.
- 1 January 2022
- Published by CMV Verlag in Reports of Biochemistry and Molecular Biology
- Vol. 10 (4) , 580-588
Association of rs2954029 and rs6982502 Variants with Coronary Artery Disease by HRM Technique: A GWAS Replication Study in an Iranian Population
Genome-wide association studies (GWAS) have been the primary tool for an unbiased study of the genetic background of coronary artery disease (CAD). They have identified a list of single-nucleotide polymorphisms (SNPs) associated with coronary artery disease (CAD). In this study, we aimed to replicate the association of rs2954029 and rs6982502, a GWAS identified SNP, to CAD in an Iranian population. A sample of 285 subjects undergoing coronary angiography, including 134 CAD patients and 151 healthy. The genotype determination of rs2954029 and rs6982502 SNPs performed using the high-resolution melting analysis (HRM) technique. Our results revealed that the TT genotype of rs2954029 (p= 0.009) and rs6982502 (p< 0.001) were significantly higher in CAD patients compared with controls. Binary logistic regression showed that rs6982502 and rs2954029 increase the risk of CAD incidence (2.470 times, p= 0.011, 95% CI= [1.219-4.751], and 2.174 times, p= 0.033, 95% CI= [1.066-4.433] respectively). After adjusting for confounders, we found that rs6982502 and rs2954029 are significantly associated with CAD risk. These data showed that the TT genotype of rs2954029 and rs6982502 is associated with the risk of CAD in a hospital-based sample of the Iranian population, which has replicated the result of recent GWAS studies.
- 1 January 2022
- Published by CMV Verlag in Reports of Biochemistry and Molecular Biology
- Vol. 10 (4) , 580-588
Association of rs2954029 and rs6982502 Variants with Coronary Artery Disease by HRM Technique: A GWAS Replication Study in an Iranian Population
Genome-wide association studies (GWAS) have been the primary tool for an unbiased study of the genetic background of coronary artery disease (CAD). They have identified a list of single-nucleotide polymorphisms (SNPs) associated with coronary artery disease (CAD). In this study, we aimed to replicate the association of rs2954029 and rs6982502, a GWAS identified SNP, to CAD in an Iranian population. A sample of 285 subjects undergoing coronary angiography, including 134 CAD patients and 151 healthy. The genotype determination of rs2954029 and rs6982502 SNPs performed using the high-resolution melting analysis (HRM) technique. Our results revealed that the TT genotype of rs2954029 (p= 0.009) and rs6982502 (p< 0.001) were significantly higher in CAD patients compared with controls. Binary logistic regression showed that rs6982502 and rs2954029 increase the risk of CAD incidence (2.470 times, p= 0.011, 95% CI= [1.219-4.751], and 2.174 times, p= 0.033, 95% CI= [1.066-4.433] respectively). After adjusting for confounders, we found that rs6982502 and rs2954029 are significantly associated with CAD risk. These data showed that the TT genotype of rs2954029 and rs6982502 is associated with the risk of CAD in a hospital-based sample of the Iranian population, which has replicated the result of recent GWAS studies.
- Open Access
- 22 February 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (5) , e23741
The gene expression of long non‐coding RNAs (lncRNAs): MEG3 and H19 in adipose tissues from obese women and its association with insulin resistance and obesity indices
Background: There is evidence regarding the role of two lncRNAs: MEG3 and H19 the pathomechanism of obesity and related disorders. Here, we aimed to evaluate the expression of MEG3 and H19 in visceral adipose tissues (VAT) and subcutaneous adipose tissues (SAT) of obese women (n = 18), as compared to normal‐weight women (n = 17). Moreover, we sought to identify the association of expression of MEG3 and H19 in SAT and VAT with obesity parameters, insulin resistance, and the mRNA expression of possible target genes involved in adipogenesis and lipogenesis including peroxisome proliferator‐activated receptor gamma (PPARγ), fatty acid synthase (FAS), and acetyl‐CoA carboxylase (ACC).Methods: Real‐time PCR was performed to investigate the mRNA expression of the above‐mentioned genes in VAT and SAT from all participants.Results: The results showed lower mRNA levels of H19 in SAT of obese women, compared to normal‐weight women, while MEG3 expression was significantly higher in the SAT of the obese group rather than controls. Correlation analysis indicated that the transcript level of H19 had an inverse correlation with obesity indices and HOMA‐IR values. However, MEG3 expression displayed a positive correlation with all the indicated parameters in all participants. Interestingly, a positive correlation was found between transcript level of MEG3 in SAT with FAS and PPARγ. However, there was an inverse correlation between SAT expression of H19 and FAS.Conclusions: It appears that lncRNAs, MEG3 and H19, are involved in obesity‐related conditions. However, more clinical studies are still required to clarify the relationships between lncRNAs with obesity and related abnormalities.
- 22 February 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (5) , e23741
Open AccessThe gene expression of long non‐coding RNAs (lncRNAs): MEG3 and H19 in adipose tissues from obese women and its association with insulin resistance and obesity indices
Background: There is evidence regarding the role of two lncRNAs: MEG3 and H19 the pathomechanism of obesity and related disorders. Here, we aimed to evaluate the expression of MEG3 and H19 in visceral adipose tissues (VAT) and subcutaneous adipose tissues (SAT) of obese women (n = 18), as compared to normal‐weight women (n = 17). Moreover, we sought to identify the association of expression of MEG3 and H19 in SAT and VAT with obesity parameters, insulin resistance, and the mRNA expression of possible target genes involved in adipogenesis and lipogenesis including peroxisome proliferator‐activated receptor gamma (PPARγ), fatty acid synthase (FAS), and acetyl‐CoA carboxylase (ACC).Methods: Real‐time PCR was performed to investigate the mRNA expression of the above‐mentioned genes in VAT and SAT from all participants.Results: The results showed lower mRNA levels of H19 in SAT of obese women, compared to normal‐weight women, while MEG3 expression was significantly higher in the SAT of the obese group rather than controls. Correlation analysis indicated that the transcript level of H19 had an inverse correlation with obesity indices and HOMA‐IR values. However, MEG3 expression displayed a positive correlation with all the indicated parameters in all participants. Interestingly, a positive correlation was found between transcript level of MEG3 in SAT with FAS and PPARγ. However, there was an inverse correlation between SAT expression of H19 and FAS.Conclusions: It appears that lncRNAs, MEG3 and H19, are involved in obesity‐related conditions. However, more clinical studies are still required to clarify the relationships between lncRNAs with obesity and related abnormalities.
- Open Access
- 26 January 2021
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 13 (1) , 1-11
The circulating levels of CTRP1 and CTRP5 are associated with obesity indices and carotid intima-media thickness (cIMT) value in patients with type 2 diabetes: a preliminary study
Background: There is growing evidence that the C1qTNF-related protein (CTRP) family has a crucial role in the pathophysiology of metabolic disorders such as type 2 diabetes (T2D) and obesity. We sought to identify the association of CTRP1 and CTRP5 circulating levels with various obesity parameters such as visceral adipose tissue (VAT) thickness, visceral adiposity index (VAI), and with carotid intima-media thickness (cIMT) in patients with T2D and controls. Methods: This preliminary study consisted of men with T2D (n = 42) and men without T2D (n = 42). The measurement of cIMT and VAT thickness was performed using an Accuvix XQ ultrasound. Circulating levels of CTRP1, CTRP5, and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA). Results: CTRP-1 and CTRP1/CTRP5 ratio were markedly higher in patients with T2D compared to controls (p < 0001 and p = 0004 respectively). Interestingly, binominal logistic regression revealed that a higher circulating level of CTRP1 was associated with the presence of T2D (odds ratio [OR]: 1.009 [95% CI: 1.004–1.015]; P = .001). CTRP1 circulating levels were correlated with WHR, VAT, and HOMA-IR in the whole population study. Also, we observed that the ratio of CTRP1 to CTRP5 in plasma (β = 0.648, P = 0.005) and CTRP5 circulating levels (β = 0.444, P = 0.049) are independently associated with cIMT value. Conclusions: Our results indicated that CTRP1 and CTRP5 concentrations were correlated with atherosclerosis in men with T2D and these adipokines might have a causal role for cardiometabolic risk in T2D.However, more studies in large sample sizes are required to clarify the role of CTRPs in T2D pathogenesis.
- 26 January 2021
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 13 (1) , 1-11
Open AccessThe circulating levels of CTRP1 and CTRP5 are associated with obesity indices and carotid intima-media thickness (cIMT) value in patients with type 2 diabetes: a preliminary study
Background: There is growing evidence that the C1qTNF-related protein (CTRP) family has a crucial role in the pathophysiology of metabolic disorders such as type 2 diabetes (T2D) and obesity. We sought to identify the association of CTRP1 and CTRP5 circulating levels with various obesity parameters such as visceral adipose tissue (VAT) thickness, visceral adiposity index (VAI), and with carotid intima-media thickness (cIMT) in patients with T2D and controls. Methods: This preliminary study consisted of men with T2D (n = 42) and men without T2D (n = 42). The measurement of cIMT and VAT thickness was performed using an Accuvix XQ ultrasound. Circulating levels of CTRP1, CTRP5, and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA). Results: CTRP-1 and CTRP1/CTRP5 ratio were markedly higher in patients with T2D compared to controls (p < 0001 and p = 0004 respectively). Interestingly, binominal logistic regression revealed that a higher circulating level of CTRP1 was associated with the presence of T2D (odds ratio [OR]: 1.009 [95% CI: 1.004–1.015]; P = .001). CTRP1 circulating levels were correlated with WHR, VAT, and HOMA-IR in the whole population study. Also, we observed that the ratio of CTRP1 to CTRP5 in plasma (β = 0.648, P = 0.005) and CTRP5 circulating levels (β = 0.444, P = 0.049) are independently associated with cIMT value. Conclusions: Our results indicated that CTRP1 and CTRP5 concentrations were correlated with atherosclerosis in men with T2D and these adipokines might have a causal role for cardiometabolic risk in T2D.However, more studies in large sample sizes are required to clarify the role of CTRPs in T2D pathogenesis.
- Open Access
- 14 January 2021
- Published by Springer Nature in Research Square
The Circulating Levels of CTRP1 and CTRP5 Are Associated with Obesity Indices and Carotid Intima-Media Thickness (cIMT) Value in Patients with Type 2 Diabetes: A Preliminary Study
Background: There is growing evidence that the C1qTNF-related protein (CTRP) family has a crucial role in the physiology and pathophysiology of metabolic disorders such as Type 2 Diabetes (T2D) and obesity. We sought to identify the association of CTRP1 and CTRP5 circulating levels with various obesity parameters such as visceral adipose tissue (VAT) thickness, visceral adiposity index (VAI), and with carotid intima-media thickness (cIMT) in patients with T2D and healthy subjects. Methods: This preliminary study consisted of men with T2D (n=42) and men without T2D (n=42). cIMT and VAT thickness measurement was performed using an Accuvix XQ ultrasound. Circulating levels of CTRP1, CTRP5, and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA).Results: CTRP-1 and CTRP1/CTRP5 ratio was markedly higher in patients with T2D compared to controls (p < 0001 and p = 0004 respectively). Interestingly, binominal logistic regression revealed that a higher circulating level of CTRP1 was associated with the presence of T2D (odds ratio [OR]: 1.009 [95% CI: 1.004-1.015]; P=.001). CTRP1 circulating levels were correlated with WHR, VAT, and HOMA-IR in the whole population study. Also, we observed that the ratio of CTRP1 to CTRP5 in plasma (β = 0.648, P=0.005) and CTRP5 circulating levels (β = 0.444, P=0.049) are independently associated with cIMT value.Conclusions: Our results indicated that CTRP1 and CTRP5 concentrations were correlated with atherosclerosis in men with T2D and these adipokines might have a causal role for cardiometabolic risk in T2D.However, more studies in large sample sizes are required to clarify the role of CTRPs in T2D pathogenesis.
- 14 January 2021
- Published by Springer Nature in Research Square
Open AccessThe Circulating Levels of CTRP1 and CTRP5 Are Associated with Obesity Indices and Carotid Intima-Media Thickness (cIMT) Value in Patients with Type 2 Diabetes: A Preliminary Study
Background: There is growing evidence that the C1qTNF-related protein (CTRP) family has a crucial role in the physiology and pathophysiology of metabolic disorders such as Type 2 Diabetes (T2D) and obesity. We sought to identify the association of CTRP1 and CTRP5 circulating levels with various obesity parameters such as visceral adipose tissue (VAT) thickness, visceral adiposity index (VAI), and with carotid intima-media thickness (cIMT) in patients with T2D and healthy subjects. Methods: This preliminary study consisted of men with T2D (n=42) and men without T2D (n=42). cIMT and VAT thickness measurement was performed using an Accuvix XQ ultrasound. Circulating levels of CTRP1, CTRP5, and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA).Results: CTRP-1 and CTRP1/CTRP5 ratio was markedly higher in patients with T2D compared to controls (p < 0001 and p = 0004 respectively). Interestingly, binominal logistic regression revealed that a higher circulating level of CTRP1 was associated with the presence of T2D (odds ratio [OR]: 1.009 [95% CI: 1.004-1.015]; P=.001). CTRP1 circulating levels were correlated with WHR, VAT, and HOMA-IR in the whole population study. Also, we observed that the ratio of CTRP1 to CTRP5 in plasma (β = 0.648, P=0.005) and CTRP5 circulating levels (β = 0.444, P=0.049) are independently associated with cIMT value.Conclusions: Our results indicated that CTRP1 and CTRP5 concentrations were correlated with atherosclerosis in men with T2D and these adipokines might have a causal role for cardiometabolic risk in T2D.However, more studies in large sample sizes are required to clarify the role of CTRPs in T2D pathogenesis.
- Open Access
- 1 May 2020
- Published by CMV Verlag in Reports of Biochemistry and Molecular Biology
- Vol. 9 (1) , 71-81
Increased mRNA Expression of CTRP3 and CTRP9 in Adipose Tissue from Obese Women: Is it Linked to Obesity-Related Parameters and mRNA Expression of Inflammatory Cytokines?
Background: Obesity, a medical condition with impaired adipokine secretion and function, has a detrimental effect on insulin and glucose metabolism. CTRP3 and CTRP9 are adipokines with possible roles in energy homeostasis regulation. We sought to compare CTRP3, CTRP9, and inflammatory gene expression in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) ...
- 1 May 2020
- Published by CMV Verlag in Reports of Biochemistry and Molecular Biology
- Vol. 9 (1) , 71-81
Open AccessIncreased mRNA Expression of CTRP3 and CTRP9 in Adipose Tissue from Obese Women: Is it Linked to Obesity-Related Parameters and mRNA Expression of Inflammatory Cytokines?
Background: Obesity, a medical condition with impaired adipokine secretion and function, has a detrimental effect on insulin and glucose metabolism. CTRP3 and CTRP9 are adipokines with possible roles in energy homeostasis regulation. We sought to compare CTRP3, CTRP9, and inflammatory gene expression in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) ...
- 1 January 2020
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 66 (04/2020) , 579-587
Emerging Role of miR-372 and miR-101a in Head and Neck Squamous Cell Carcinoma
Background: microRNAs (miRNAs) have an important role in cancer development and progression. It has been shown that miR-372 and miR-101 are involved in cancer progression. In the present study we evaluated expressions of these miRNAs and their serum levels in patients with head and neck squamous cell carcinoma (HNSCC) and controls. Methods: We conducted this case-control study on 60 patients with HNSCC and 30 controls. Patients were diagnosed by histological assessments of their tissues. Expressions of EGFR, PTEN, PI3K/CA, miR-372, and miR-101a were evaluated in the tissues, along with serum levels of the miRNAs. Results: Tissue expression of PTEN decreased in HNSCC, and expressions of EGFR and PI3K increased in HNSCC tissues compared to the controls. Tissue expressions of miR-372 increased and miR-101a decreased in HNSCC tissues compared to the controls. We observed significantly lower serum levels of miR-101a in patients; however, these findings for miR-372 were not significant. A strong correlation existed between serum levels and tissue expression of miR-101a. Notably, miR-101a serum levels showed good sensitivity and specificity for diagnosis of HNSCC. Conclusions: The results showed that HNSCC patients had higher tissue expression of miR-372 and lower expression of miR-101a. Also, serum levels of miR-101a were lower in HNSCC patients. We observed that miR-101a had good sensitivity and specificity for diagnosis of HNSCC. The present study suggested that miR-101a could be a potential biomarker for HNSCC.
- 1 January 2020
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 66 (04/2020) , 579-587
Emerging Role of miR-372 and miR-101a in Head and Neck Squamous Cell Carcinoma
Background: microRNAs (miRNAs) have an important role in cancer development and progression. It has been shown that miR-372 and miR-101 are involved in cancer progression. In the present study we evaluated expressions of these miRNAs and their serum levels in patients with head and neck squamous cell carcinoma (HNSCC) and controls. Methods: We conducted this case-control study on 60 patients with HNSCC and 30 controls. Patients were diagnosed by histological assessments of their tissues. Expressions of EGFR, PTEN, PI3K/CA, miR-372, and miR-101a were evaluated in the tissues, along with serum levels of the miRNAs. Results: Tissue expression of PTEN decreased in HNSCC, and expressions of EGFR and PI3K increased in HNSCC tissues compared to the controls. Tissue expressions of miR-372 increased and miR-101a decreased in HNSCC tissues compared to the controls. We observed significantly lower serum levels of miR-101a in patients; however, these findings for miR-372 were not significant. A strong correlation existed between serum levels and tissue expression of miR-101a. Notably, miR-101a serum levels showed good sensitivity and specificity for diagnosis of HNSCC. Conclusions: The results showed that HNSCC patients had higher tissue expression of miR-372 and lower expression of miR-101a. Also, serum levels of miR-101a were lower in HNSCC patients. We observed that miR-101a had good sensitivity and specificity for diagnosis of HNSCC. The present study suggested that miR-101a could be a potential biomarker for HNSCC.